The Phospho-COT (Thr290) antibody is designed to detect the phosphorylated form of COT (Cancer Osaka Thyroid, also known as MAP3K8 or TPL2), a serine/threonine kinase involved in inflammatory and oncogenic signaling. COT activates multiple pathways, including NF-κB and ERK/MAPK, by phosphorylating downstream targets like IκBα and MEK1/2. Its activity is tightly regulated through post-translational modifications, including phosphorylation at Thr290. This residue lies within the kinase domain, and its phosphorylation is critical for COT's catalytic activity, stability, and interaction with regulatory proteins such as p105 (NF-κB1). Dysregulation of COT signaling is linked to autoimmune diseases, inflammation, and cancers, particularly those driven by chronic inflammation.
The Phospho-COT (Thr290) antibody enables researchers to study COT activation status in response to stimuli such as cytokines (e.g., TNF-α, IL-1β) or stress signals. It is commonly used in techniques like Western blotting, immunoprecipitation, and immunofluorescence to assess COT activation dynamics in cell lines, tissues, or disease models. Validation typically includes testing in COT-deficient cells or using phosphatase treatments to confirm phosphorylation specificity. This antibody aids in exploring COT's role in pathological contexts, including its crosstalk with other kinases and potential as a therapeutic target. Species reactivity generally covers human, mouse, and rat samples, depending on the product.